Loading…
Based on limited metadata from an FDA Warning Letter issued to Windlas Healthcare Private Limited on March 10, 2020, the agency identified compliance concerns related to drug manufacturing or distribution operations. Without access to the full letter text or specific subject line details, the precise nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific manufacturing facility or issuing field office is not indicated in the metadata provided. Additional documentation would be needed to clarify the specific cGMP, labeling, or other regulatory deficiencies cited by the agency.